Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 41

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1B
Chunk 41
---

     
    Director

    Richard Barry

    /s/ Deirdre Connelly
     
    Director

    Deirdre Connelly

    /s/ Kathryn Boor
     
    Director

    Kathryn J. Boor, Ph.D.

    /s/ Michael A. Chambers
     
    Director

    Michael A. Chambers

    /s/ Stephen L. Mayo
     
    Director

    Stephen L. Mayo, Ph.D.

    /s/ Claude Nicaise
     
    Director

    Claude Nicaise, MD

    /s/ Hans Wigzell
     
    Director

    Hans Wigzell, M.D., Ph.D.

-92-

SAREPTA THERAPEUTICS, INC.

CONSOLIDATED FINANCIAL STATEMENTS

    PageNumber

    Report of Independent Registered Public Accounting Firm (KPMG LLP, Boston, MA, Auditor Firm ID: 185)
     
    F-2

    Consolidated Balance Sheets
     
    F-4

    Consolidated Statements of Comprehensive Income (Loss)
     
    F-5

    Consolidated Statements of Stockholders’ Equity
     
    F-6

    Consolidated Statements of Cash Flows
     
    F-7

    Notes to Consolidated Financial Statements
     
    F-8

F-1

Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors

Sarepta Therapeutics, Inc.:

Opinions on the Consolidated Financial Statements and Internal Control Over Financial Reporting

We have audited the accompanying consolidated balance sheets of Sarepta Therapeutics, Inc. and subsidiaries (the Company) as of December 31, 2024 and 2023, the related consolidated statements of comprehensive income (loss), stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively, the consolidated financial statements). We also have audited the Company’s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.  In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for